Urovant Sciences Ltd (NASDAQ:UROV) – Jefferies Financial Group cut their Q3 2020 earnings per share estimates for Urovant Sciences in a report issued on Wednesday, November 6th. Jefferies Financial Group analyst B. Amin now anticipates that the company will earn ($0.93) per share for the quarter, down from their previous forecast of ($0.86). Jefferies Financial Group also issued estimates for Urovant Sciences’ Q4 2020 earnings at ($1.65) EPS, FY2020 earnings at ($4.38) EPS, FY2021 earnings at ($4.23) EPS, FY2022 earnings at ($2.72) EPS, FY2023 earnings at ($0.56) EPS and FY2024 earnings at $0.67 EPS.
Several other brokerages have also recently issued reports on UROV. Zacks Investment Research cut shares of Urovant Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday. HC Wainwright set a $28.00 target price on shares of Urovant Sciences and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, ValuEngine cut shares of Urovant Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $21.44.
Urovant Sciences (NASDAQ:UROV) last announced its earnings results on Tuesday, November 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.30.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Perceptive Advisors LLC raised its position in shares of Urovant Sciences by 116.7% during the 2nd quarter. Perceptive Advisors LLC now owns 1,875,426 shares of the company’s stock valued at $14,835,000 after buying an additional 1,010,067 shares in the last quarter. FMR LLC raised its position in shares of Urovant Sciences by 28.4% during the 1st quarter. FMR LLC now owns 1,710,836 shares of the company’s stock valued at $17,194,000 after buying an additional 378,135 shares in the last quarter. Atria Investments LLC purchased a new stake in shares of Urovant Sciences during the 2nd quarter valued at about $3,420,000. Sio Capital Management LLC grew its holdings in Urovant Sciences by 2.3% during the 2nd quarter. Sio Capital Management LLC now owns 220,042 shares of the company’s stock valued at $1,741,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Urovant Sciences by 7.3% during the 2nd quarter. Vanguard Group Inc. now owns 131,487 shares of the company’s stock valued at $1,040,000 after purchasing an additional 9,000 shares during the last quarter. Hedge funds and other institutional investors own 24.23% of the company’s stock.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.